

**Compliance Expert Speaks at BIO IT Coalition
on the FDA's Quality by Design**Cerulean Associates LLC
<http://www.ceruleanllc.com>

FOR IMMEDIATE RELEASE

February 6, 2008 – Washington, D.C. – A packed room of executives, lawyers and business owners listened to a rousing talk on how to get their FDA-regulated new products to market in two-thirds the time it takes their competitors.

Hosted by the *BIO IT Coalition*, the speech took place on January 23rd at the Arlington, Virginia Economic Development offices and was given by Cerulean Associates' Managing Director, John Avellanet.

After a review of client case studies, Mr. Avellanet provided attendees a number of key strategies, including how to improve their pipeline success rate and ways to better leverage universities and academia.

Attendees also received reprints of Mr. Avellanet's recent articles on biotech and pharmaceutical development, *Quality by Design: Defining Your Preclinical Package* and *How Part 11 Compliance Impacts QbD*.

Slides from the presentation are available in the [News & Media Center](#) of the Cerulean website (www.ceruleanllc.com).

John Avellanet is a leading international expert and consultant on the FDA's Quality by Design, a regular columnist for the international *Journal of Commercial Biotechnology*, and a co-author of the book, [Best Practices in Biotechnology Business Development](#).

Through his consultancy, **Cerulean Associates LLC**, Mr. Avellanet advises executives on cost-effective regulatory compliance, flexible quality systems, preventing intellectual property theft, and achieving faster time to market. On the web at www.ceruleanllc.com.

###

For more information, contact:

John Avellanet
Managing Director
Cerulean Associates LLC
PO Box 498
Williamsburg, VA 23187 USA
+1.757.645.2864
info@ceruleanllc.com

